275 related articles for article (PubMed ID: 8934531)
1. ECA39 is regulated by c-Myc in human and by a Jun/Fos homolog, Gcn4, in yeast.
Ben-Yosef T; Yanuka O; Benvenisty N
Oncogene; 1996 Nov; 13(9):1859-66. PubMed ID: 8934531
[TBL] [Abstract][Full Text] [Related]
2. ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell cycle regulation in yeast.
Schuldiner O; Eden A; Ben-Yosef T; Yanuka O; Simchen G; Benvenisty N
Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7143-8. PubMed ID: 8692959
[TBL] [Abstract][Full Text] [Related]
3. Involvement of Myc targets in c-myc and N-myc induced human tumors.
Ben-Yosef T; Yanuka O; Halle D; Benvenisty N
Oncogene; 1998 Jul; 17(2):165-71. PubMed ID: 9674700
[TBL] [Abstract][Full Text] [Related]
4. Position and orientation independent transactivation by c-Myc.
Packham G; Bello-Fernandez C; Cleveland JL
Cell Mol Biol Res; 1994; 40(7-8):699-706. PubMed ID: 7787888
[TBL] [Abstract][Full Text] [Related]
5. Expression of the TAF4b gene is induced by MYC through a non-canonical, but not canonical, E-box which contributes to its specific response to MYC.
Teye K; Okamoto K; Tanaka Y; Umata T; Ohnuma M; Moroi M; Kimura H; Tsuneoka M
Int J Oncol; 2008 Dec; 33(6):1271-80. PubMed ID: 19020761
[TBL] [Abstract][Full Text] [Related]
6. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
[TBL] [Abstract][Full Text] [Related]
7. A DNA microarray screen for genes involved in c-MYC and N-MYC oncogenesis in human tumors.
Schuldiner O; Benvenisty N
Oncogene; 2001 Aug; 20(36):4984-94. PubMed ID: 11526483
[TBL] [Abstract][Full Text] [Related]
8. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
[TBL] [Abstract][Full Text] [Related]
9. Jun DNA-binding is modulated by mutations between the leucines or by direct interaction of fos with the TGACTCA sequence.
Hirai S; Yaniv M
New Biol; 1989 Nov; 1(2):181-91. PubMed ID: 2562220
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
[TBL] [Abstract][Full Text] [Related]
11. In vivo regulation of single copy and amplified N-myc in human neuroblastoma cells.
Lutz W; Schwab M
Oncogene; 1997 Jul; 15(3):303-15. PubMed ID: 9233765
[TBL] [Abstract][Full Text] [Related]
12. C-myc and the yeast transcription factor PHO4 share a common CACGTG-binding motif.
Fisher F; Jayaraman PS; Goding CR
Oncogene; 1991 Jul; 6(7):1099-104. PubMed ID: 1861859
[TBL] [Abstract][Full Text] [Related]
13. The role of immunoglobulin kappa elements in c-myc activation.
Hörtnagel K; Mautner J; Strobl LJ; Wolf DA; Christoph B; Geltinger C; Polack A
Oncogene; 1995 Apr; 10(7):1393-401. PubMed ID: 7731690
[TBL] [Abstract][Full Text] [Related]
14. Artificial oncoproteins: modified versions of the yeast bZip protein GCN4 induce cellular transformation.
Nishizawa M; Fu SL; Kataoka K; Vogt PK
Oncogene; 2003 Sep; 22(39):7931-41. PubMed ID: 12970741
[TBL] [Abstract][Full Text] [Related]
15. Mouse and rat B-myc share amino acid sequence homology with the c-myc transcriptional activator domain and contain a B-myc specific carboxy terminal region.
Asker CE; Magnusson KP; Piccoli SP; Andersson K; Klein G; Cole MD; Wiman KG
Oncogene; 1995 Nov; 11(10):1963-9. PubMed ID: 7478514
[TBL] [Abstract][Full Text] [Related]
16. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
Habel ME; Lemieux R; Jung D
J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
[TBL] [Abstract][Full Text] [Related]
17. Autorepression of c-myc requires both initiator and E2F-binding site elements and cooperation with the p107 gene product.
Luo Q; Li J; Cenkci B; Kretzner L
Oncogene; 2004 Feb; 23(5):1088-97. PubMed ID: 14716294
[TBL] [Abstract][Full Text] [Related]
18. A novel factor distinct from E2F mediates C-MYC promoter activation through its E2F element during exit from quiescence.
Alvaro-Blanco J; Martínez-Gac L; Calonge E; Rodríguez-Martínez M; Molina-Privado I; Redondo JM; Alcamí J; Flemington EK; Campanero MR
Carcinogenesis; 2009 Mar; 30(3):440-8. PubMed ID: 19126644
[TBL] [Abstract][Full Text] [Related]
19. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation.
Greenberg RA; O'Hagan RC; Deng H; Xiao Q; Hann SR; Adams RR; Lichtsteiner S; Chin L; Morin GB; DePinho RA
Oncogene; 1999 Feb; 18(5):1219-26. PubMed ID: 10022128
[TBL] [Abstract][Full Text] [Related]
20. Repression of alpha-fetoprotein gene expression under hypoxic conditions in human hepatoma cells: characterization of a negative hypoxia response element that mediates opposite effects of hypoxia inducible factor-1 and c-Myc.
Mazure NM; Chauvet C; Bois-Joyeux B; Bernard MA; Nacer-Chérif H; Danan JL
Cancer Res; 2002 Feb; 62(4):1158-65. PubMed ID: 11861398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
